CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

23 1 2024 08:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

09 1 2024 08:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

18 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 11 2023 08:00:01 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

02 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

17 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

16 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023

03 10 2023 08:00:00 提供 Nasdaq GlobeNewswire